Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis

Ocaña, A., Vera-Badillo, F., Al-Mubarak, M., Templeton, A. J., Corrales‐Sánchez, V., Díez-González, L., Cuenca-López, M. D., Šeruga, B., Pandiella, A., & Amir, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095219 · Cited by 169

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

Knowles, M. A., Platt, F. M., Ross, R. L., & Hurst, C. D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9198-3 · Cited by 168

The Natural Anticancer Compounds Rocaglamides Inhibit the Raf-MEK-ERK Pathway by Targeting Prohibitin 1 and 2

Polier, G., Neumann, J., Thuaud, F., Ribeiro, N., Gelhaus, C., Schmidt, H., Giaisi, M., Köhler, R., Müller, W. W., Proksch, P., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.012 · Cited by 166

Chronotherapy and the molecular clock: Clinical implications in oncology☆

Innominato, P. F., Lévi, F., & Bjarnason, G. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.06.002 · Cited by 168

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia

Tasian, S. K., Teachey, D. T., Li, Y., Shen, F., Harvey, R. C., Chen, I., Ryan, T. M., Vincent, T. L., Willman, C. L., Perl, A. E., et al. (2016) · Blood · doi:10.1182/blood-2016-05-707653 · Cited by 163

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer

Vansteenkiste, J., Canon, J.-L. R., de Braud, F., Grossi, F., Pas, T. M. D., Gray, J. E., Su, W., Felip, E., Yoshioka, H., Gridelli, C., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000607 · Cited by 163

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

Andersen, J. N., Sathyanarayanan, S., Bacco, A. D., Chi, A., Zhang, T., Chen, A. H., Dolinski, B. M., Kraus, M., Roberts, B. S., Arthur, W. T., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001065 · Cited by 164

Targeting cancer by binding iron: Dissecting cellular signaling pathways

Lui, G. Y. L., Kovačević, Ž., Richardson, V., Merlot, A. M., Kalinowski, D. S., & Richardson, D. R. (2015) · Oncotarget · doi:10.18632/oncotarget.4349 · Cited by 165

Salvianolic acid A attenuates CCl4-induced liver fibrosis by regulating the PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways

Wang, R., Song, F., Li, S., Wu, B., Gu, Y., & Yuan, Y. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s194787 · Cited by 162

Metabolic consequences of oncogenic IDH mutations

Parker, S. J., & Metallo, C. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.003 · Cited by 162

Osteosarcoma.

Gorlick, R., & Khanna, C. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.77 · Cited by 157

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

Sommer, E. M., Dry, H., Cross, D. A. E., Guichard, S. M., Davies, B. R., & Alessi, D. R. (2013) · Biochemical Journal · doi:10.1042/bj20130342 · Cited by 166

The PI 3 K / A kt/m TOR axis in head and neck cancer: functions, aberrations, cross‐talk, and therapies

Broek, R. V., Mohan, S., Eytan, D. F., Chen, Z., & Waes, C. V. (2013) · Oral Diseases · doi:10.1111/odi.12206 · Cited by 159

The Hepatitis B Virus (HBV) HBx Protein Activates AKT To Simultaneously Regulate HBV Replication and Hepatocyte Survival

Rawat, S., & Bouchard, M. J. (2014) · Journal of Virology · doi:10.1128/jvi.02440-14 · Cited by 157

Unraveling the AMPK-SIRT1-FOXO Pathway: The In-Depth Analysis and Breakthrough Prospects of Oxidative Stress-Induced Diseases

Guan, G., Chen, Y., & Dong, Y. (2025) · Antioxidants · doi:10.3390/antiox14010070 · Cited by 175

Trial Watch

Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25238 · Cited by 160

Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway

Ching, C. B., & Hansel, D. E. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.133 · Cited by 155

Redox Regulation in Cancer Stem Cells

Ding, S., Li, C., Cheng, N., Cui, X., Xu, X., & Zhou, G. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/750798 · Cited by 159

Ketogenic diets: from cancer to mitochondrial diseases and beyond

Branco, A. F., Ferreira, A., Simões, R. F., Novais, S. M., Zehowski, C., Cope, E., Silva, A. M., Pereira, D. J., Sardão, V. A., & Cunha‐Oliveira, T. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12591 · Cited by 152

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway

Klempner, S. J., Myers, A. P., & Cantley, L. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0063 · Cited by 148

PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth

Sharma, N., Nanta, R., Sharma, J. P., Gunewardena, S., Singh, K. P., Shankar, S., & Srivastava, R. K. (2015) · Oncotarget · doi:10.18632/oncotarget.5055 · Cited by 151

FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway

Lin, A., Piao, H.-L., Li, Z., Sarbassov, D. D., Ma, L., & Gan, B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1729 · Cited by 152

PDK1 Signaling Toward PLK1–MYC Activation Confers Oncogenic Transformation, Tumor-Initiating Cell Activation, and Resistance to mTOR-Targeted Therapy

Tan, J. Y., Li, Z., Lee, P. L., Guan, P., Aau, M. Y., Lee, S. T., Feng, M., Lim, C. Z., Lee, E. Y. J., Wee, Z. N., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0595 · Cited by 150

Therapeutic Targeting of Myc

Prochownik, E. V., & Vogt, P. K. (2010) · Genes & Cancer · doi:10.1177/1947601910377494 · Cited by 154

The regulation of cellular metabolism by tumor suppressor p53

Liang, Y., Liu, J., & Feng, Z. (2013) · Cell & Bioscience · doi:10.1186/2045-3701-3-9 · Cited by 154

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

Guglielmelli, P., Barosi, G., Rambaldi, A., Marchioli, R., Masciulli, A., Tozzi, L., Biamonte, F., Bartalucci, N., Gattoni, E., Lupo, L., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330563 · Cited by 149

G Protein–Coupled Receptor–Mediated Activation of p110β by Gβγ Is Required for Cellular Transformation and Invasiveness

Dbouk, H. A., Vadas, O., Shymanets, A., Burke, J. E., Salamon, R. S., Khalil, B. D., Barrett, M. O., Waldo, G. L., Surve, C. R., Hsueh, C., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2003264 · Cited by 149

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Beaufils, F., Cmiljanović, N., Cmiljanović, V., Bohnacker, T., Melone, A., Marone, R., Jackson, E., Zhang, X., Sele, A., Borsari, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00930 · Cited by 150

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

Ross, J. S., Wang, K., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., Otto, G. A., He, J., Palmer, G. A., Yelensky, R., Lipson, D., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.135 · Cited by 149

Mechanisms linking obesity and cancer

Louie, S. M., Roberts, L. S., & Nomura, D. K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.02.008 · Cited by 152

Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer

Loi, S., Michiels, S., Lambrechts, D., Fumagalli, D., Claes, B., Kellokumpu‐Lehtinen, P., Bono, P., Kataja, V. V., Piccart, M. J., Joensuu, H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt121 · Cited by 147

Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer

Jones, L. W., Antonelli, J. A., Masko, E. M., Broadwater, G., Lascola, C. D., Fels, D. R., Dewhirst, M. W., Dyck, J. R. B., Nagendran, J., Flores, C., et al. (2012) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01575.2011 · Cited by 154

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 148

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z. Y., Wang, B., Shao, Z., Wang, Z., & Hu, X. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-248 · Cited by 149

Cancer and mTOR Inhibitors in Transplant Recipients

de Fijter, J. W. (2016) · Transplantation · doi:10.1097/tp.0000000000001447 · Cited by 149

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer.

Yip, P. Y. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.01.04 · Cited by 144

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

Inno, A., Bogina, G. S., Turazza, M., Bortesi, L., Duranti, S., Massocco, A., Zamboni, G., Carbognin, G., Alongi, F., Salgarello, M., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0309 · Cited by 148

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood · doi:10.1182/blood-2014-03-559963 · Cited by 142

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment

Cheng, H., Shcherba, M., Pendurti, G., Liang, Y., Piperdi, B., & Perez-Soler, R. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.72 · Cited by 145

Akt activation: A potential strategy to ameliorate insulin resistance

Zhang, Z., Liu, H., & Liu, J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.004 · Cited by 143

Hodgkin lymphoma: 2018 update on diagnosis, risk‐stratification, and management

Ansell, S. M. (2018) · American Journal of Hematology · doi:10.1002/ajh.25071 · Cited by 142

Cell Survival and Apoptosis Signaling as Therapeutic Target for Cancer: Marine Bioactive Compounds

Kalimuthu, S., & Kim, S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14022334 · Cited by 145

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma

Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140

The emergence of drug resistance to targeted cancer therapies: Clinical evidence

Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145

Management of toxicity to isoform α-specific PI3K inhibitors

Nunnery, S. E., & Mayer, I. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz440 · Cited by 137

Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway

Wang, T., Seah, S., Loh, X.-Y., Chan, C. W., Hartman, M., Goh, B.-C., & Lee, S. C. (2015) · Oncotarget · doi:10.18632/oncotarget.6304 · Cited by 145

Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors

Sun, J., Zhang, D., Bae, D.-H., Sahni, S., Jansson, P. J., Zheng, Y., Zhao, Q., Yue, F., Zheng, M., Kovačević, Ž., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt163 · Cited by 140

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance

Stronach, E. A., Chen, M. M., Maginn, E. N., Agarwal, R., Mills, G. B., Wasan, H. S., & Gabra, H. (2011) · Neoplasia · doi:10.1593/neo.111032 · Cited by 138

25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations

Fabbro, D. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095489 · Cited by 141

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138

Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer

Dhar, S., Kumar, A., Li, K., Tzivion, G., & Levenson, A. S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.11.004 · Cited by 137

Control of Cell Survival and Proliferation by Mammalian Eukaryotic Initiation Factor 4B

Shahbazian, D., Parsyan, A. E., Petroulakis, E., Topisirović, I., Martineau, Y., Gibbs, B. F., Svitkin, Y. V., & Sonenberg, N. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01218-09 · Cited by 137

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Mahadevan, D., Chiorean, E. G., Harris, W. B., Hoff, D. D. V., Stejskal-Barnett, A., Qi, W., Anthony, S. P., Younger, A., Rensvold, D., Cordova-Marks, F. M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.027 · Cited by 136

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. H., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J.-L., Marlow, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66343 · Cited by 140

Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds

Amin, A. R. M. R., Karpowicz, P. A., Carey, T. E., Arbiser, J. L., Nahta, R., Chen, Z. G., Dong, J., Küçük, Ö., Khan, G. N., Huang, G. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.005 · Cited by 146

Agonist-stimulated phosphatidylinositol-3,4,5-trisphosphate generation by scaffolded phosphoinositide kinases

Choi, S., Hedman, A. C., Sayedyahossein, S., Thapa, N., Sacks, D. B., & Anderson, R. A. (2016) · Nature Cell Biology · doi:10.1038/ncb3441 · Cited by 132

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab

Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133

Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen Expression

Kochuparambil, S. T., Al-Husein, B. A., Goc, A., Soliman, S., & Somanath, P. R. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174870 · Cited by 134

Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial–Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis

Yang, F., Takagaki, Y., Yoshitomi, Y., Ikeda, T., Li, J., Kitada, M., Kumagai, A., Kawakita, E., Shi, S., Kanasaki, K., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0620 · Cited by 134

PIK3CA in Colorectal Cancer

Cathomas, G. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00035 · Cited by 133

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis

Martelli, A. M., Evangelisti, C., Chiarini, F., Grimaldi, C., Cappellini, A., Ognibene, A., & McCubrey, J. A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.04.005 · Cited by 134

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

Butler, D. E., Marlein, C. R., Walker, H. F., Frame, F. M., Mann, V. M., Simms, M. S., Davies, B. R., Collins, A. T., & Maitland, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.18082 · Cited by 136

miR-125a-3p/FUT5-FUT6 axis mediates colorectal cancer cell proliferation, migration, invasion and pathological angiogenesis via PI3K-Akt pathway

Liang, L., Gao, C., Yang, L., Sun, M., Xu, J., Li, H., Li, J., & Zhao, Y. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.352 · Cited by 130

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

Corcoran, R. B., Settleman, J. E., & Engelman, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.262 · Cited by 133

Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma

Kim, S. M., Leem, S.-H., Chu, I., Park, Y.-Y., Kim, S. C., Kim, S. B., Park, E. S., Lim, J. Y., Heo, J., Kim, Y. J., et al. (2011) · Hepatology · doi:10.1002/hep.24813 · Cited by 132

Current clinical development of PI3K pathway inhibitors in glioblastoma

Wen, P. Y., Lee, E. Q., Reardon, D. A., Ligon, K. L., & Yung, W. K. A. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos117 · Cited by 133

Quantitative Proteomics Reveals that miR-155 Regulates the PI3K-AKT Pathway in Diffuse Large B-Cell Lymphoma

Huang, X., Shen, Y., Liu, M., Bi, C., Jiang, C., Iqbal, J., McKeithan, T. W., Chan, W. C., Ding, S., & Fu, K. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.013 · Cited by 131

Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth

Fu, L., Chen, W., Guo, W., Wang, J., Tian, Y., Shi, D., Zhang, X. M., Qiu, H., Xiao, X., Kang, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069240 · Cited by 129

Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases

Hon, W.-C., Berndt, A., & Williams, R. L. (2012) · Oncogene · doi:10.1038/onc.2011.532 · Cited by 129

Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation

Yamaguchi, H., Yoshida, S., Muroi, E., Yoshida, N., Kawamura, M., Kouchi, Z., Nakamura, Y., Sakai, R., & Fukami, K. (2011) · The Journal of Cell Biology · doi:10.1083/jcb.201009126 · Cited by 131

The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer

Dong, P., Konno, Y., Watari, H., Hosaka, M., Noguchi, M., & Sakuragi, N. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0231-0 · Cited by 128

Global Downstream Pathway Analysis Reveals a Dependence of Oncogenic NF-E2–Related Factor 2 Mutation on the mTOR Growth Signaling Pathway

Shibata, T., Saito, S., Kokubu, A., Suzuki, T., Yamamoto, M. P., & Hirohashi, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0384 · Cited by 133

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesisPreprint

Utermark, T., Rao, T., Cheng, H.-L. M., Wang, Q., Lee, S., Wang, Z. C., Iglehart, J. D., Roberts, T. M., Muller, W. J., & Zhao, J. J. (2012) · Genes & Development · doi:10.1101/gad.191973.112 · Cited by 132

PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells

Kolev, V. N., Wright, Q. G., Vidal, C. M., Ring, J. E., Shapiro, I. M., Ricono, J. M., Weaver, D. T., Padval, M. V., Pachter, J. A., & Xu, Q. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1223 · Cited by 127

Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling

Henry, W. S., Laszewski, T., Tsang, T., de Beça, F. F., Beck, A. H., McAllister, S. S., & Toker, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2400 · Cited by 127

The genomics and genetics of endometrial cancer

Bell, D. W., & Ohara (2012) · Advances in Genomics and Genetics · doi:10.2147/agg.s28953 · Cited by 126

Regulation of Skp2 Expression and Activity and Its Role in Cancer Progression

Chan, C., Lee, S.-W., Wang, J., & Lin, H.-K. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.89 · Cited by 125

Resveratrol inhibits proliferation and migration through SIRT1 mediated post-translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells

Chai, R., Fu, H., Zheng, Z., Liu, T., Ji, S., & Li, G. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7612 · Cited by 127

Luminal Expression of PIK3CA Mutant H1047R in the Mammary Gland Induces Heterogeneous Tumors

Meyer, D. S., Brinkhaus, H., Müller, U., Müller, M., Cardiff, R. D., & Bentires‐Alj, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3827 · Cited by 125

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy

Bian, X., Gao, J., Luo, F., Rui, C., Zheng, T., Wang, D., Wang, Y., Roberts, T. M., Liu, P., Zhao, J. J., et al. (2017) · Oncogene · doi:10.1038/onc.2017.326 · Cited by 124

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E., & Firuzi, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103749 · Cited by 129

Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases

Zhang, J., Zheng, J., Yang, Y., Lu, J., Gao, J., Lu, T., Sun, J. H., Jiang, H., Zhu, Y., Zheng, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep18678 · Cited by 126

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Shapiro, G. I., Bell‐McGuinn, K. M., Molina, J. R., Bendell, J. C., Spicer, J. F., Kwak, E. L., Pandya, S. S., Millham, R., Borzillo, G. V., Pierce, K. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1306 · Cited by 123

MicroRNA-101-mediated Akt activation and estrogen-independent growth

Sachdeva, M., Wu, H., Ru, P., Hwang, L., Trieu, V. N., & Mo, Y.-Y. (2010) · Oncogene · doi:10.1038/onc.2010.463 · Cited by 123

Co‐targeting the PI3K/ mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms

Bartalucci, N., Tozzi, L., Bogani, C., Martinelli, S., Rotunno, G., Villeval, J., & Vannucchi, A. M. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12162 · Cited by 125

Mast cell exosomes promote lung adenocarcinoma cell proliferation ¿ role of KIT-stem cell factor signaling

Xiao, H. F., Lässer, C., Shelke, G. V., Wang, J., Rådinger, M., Lunavat, T. R., Malmhäll, C., Lin, L., Li, J., Li, L., et al. (2014) · Cell Communication and Signaling · doi:10.1186/preaccept-1817458803126023 · Cited by 128

Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations

Wang, K., Russell, J. S., McDermott, J. D., Elvin, J. A., Khaira, D., Johnson, A., Jennings, T. A., Ali, S. M., Murray, M., Marshall, C. B., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2568 · Cited by 123

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

Grabinski, N., Ewald, F., Hofmann, B. T., Staufer, K., Schumacher, U., Nashan, B., & Jücker, M. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-85 · Cited by 122

PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer

YAN, L.-X., LIU, Y.-H., XIANG, J.-W., WU, Q.-N., XU, L.-B., LUO, X.-L., ZHU, X.-L., LIU, C., XU, F.-P., LUO, D.-L., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3287 · Cited by 122

Akt Pathway Inhibitors

Uko, N. E., Güner, O. F., Matesic, D. F., & Bowen, J. P. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200224101808 · Cited by 125

Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives

Cocco, S., Piezzo, M., Calabrese, A., Cianniello, D., Caputo, R., Lauro, V. D., Fusco, G., Gioia, G. D., Licenziato, M., & Laurentiis, M. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134579 · Cited by 127

Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1

Sims, J. T., Ganguly, S. S., Bennett, H., Friend, J. W., Tepe, J., & Plattner, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055509 · Cited by 121

Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammatory/Autoimmune Diseases and Hematological Malignancies

Foster, J. G., Blunt, M. D., Carter, E. P., & Ward, S. G. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004051 · Cited by 122

Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas

Yamamoto, H., Higasa, K., Sakaguchi, M., Shien, K., Soh, J., Ichimura, K., Furukawa, M., Hashida, S., Tsukuda, K., Takigawa, N., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt338 · Cited by 121

Phase II study of PX-866 in recurrent glioblastoma

Pitz, M. W., Eisenhauer, E. A., MacNeil, M. V., Thiessen, B. A., Easaw, J. C., Macdonald, D. R., Eisenstat, D. D., Kakumanu, A. S., Salim, M., Chalchal, H. I., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou365 · Cited by 121

Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer

Totiger, T. M., Srinivasan, S., Jala, V. R., Lamichhane, P., Dosch, A. R., Gaidarski, A. A., Joshi, C. G., Rangappa, S., Castellanos, J. A., Vemula, P. K., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0464 · Cited by 125

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

Sirico, M., D’Angelo, A., Gianni, C., Casadei, C., Merloni, F., & De Giorgi, U. (2023) · Cancers · doi:10.3390/cancers15030703 · Cited by 121

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer

Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 126

Targeting survivin in cancer: the cell-signalling perspective

Kanwar, J. R., Kamalapuram, S. K., & Kanwar, R. K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.04.001 · Cited by 120

Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention

Tong, X., & Pelling, J. C. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990119 · Cited by 117

Targeting the phosphoinositide 3-kinase pathway in cancer

Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,785

Targeting PI3K/Akt signal transduction for cancer therapy

He, Y., Sun, M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 2,045

Molecular targeting: PI3 kinase pathway

Dancey, J. E. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh932 · Cited by 54

Akt inhibitors in cancer therapy

Alam, M., Ali, S., & Hassan, M. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00006-5 · Cited by 6

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033